MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) – Research analysts at B. Riley issued their Q1 2023 earnings estimates for MiNK Therapeutics in a note issued to investors on Monday, November 14th. B. Riley analyst K. Patel forecasts that the company will post earnings of ($0.26) per share for the quarter. The consensus estimate for MiNK Therapeutics' current full-year earnings is ($0.84) per share. B. Riley also issued estimates for MiNK Therapeutics' Q3 2023 earnings at ($0.25) EPS and Q4 2023 earnings at ($0.28) EPS.

MiNK Therapeutics (NASDAQ:INKT – Get Rating) last posted its quarterly earnings data on Thursday, November 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04.

MiNK Therapeutics Stock Up 3.0 %

Shares of NASDAQ INKT opened at $3.16 on Wednesday. The business's 50 day moving average price is $2.27 and its 200 day moving average price is $1.92. The firm has a market cap of $106.76 million and a P/E ratio of -4.05. MiNK Therapeutics has a 52 week low of $1.09 and a 52 week high of $21.40.

Institutional Investors Weigh In On MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. First Republic Investment Management Inc. acquired a new stake in MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 81,500 shares of the company's stock, valued at approximately $172,000. First Republic Investment Management Inc. owned about 0.24% of MiNK Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 1.07% of the company's stock.

About MiNK Therapeutics

(Get Rating)

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.

Featured Articles

• Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
• Use The Airbnb Stock Implosion to Your Advantage
• 3 Natural Gas Stocks That Offer Great Dividend Yields
• International Game Technology is Well Worth the Gamble
• Why Lowe's Is Up And Home Depot Down
• The TJX Companies Could Break Out To New Highs

Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.